C-Bridge Capital

Ruiqiao Dingke Group is a medical technology group . Adhering to the core concept of "fast and high-quality scale", it gives full play to the advantages of platformization and accurately captures global industry trends and market demands.

Human Investments is the exclusive distribution partner in Korea and China for Establishment Labs Holdings. Through its subsidiaries Motiva Korea and Motiva China, Human Investments Ltd. currently markets Motiva® devices in the Korea and China markets. Motiva® Devices, known for their advanced 3D negative imprinting technology, are recognized for their superior safety and natural look and feel.

Synaptic Medical Inc. is a medical device company that develops and commercializes products aimed at treating cardiac arrhythmias and other cardiovascular diseases. Founded in 2005, the company operates from its headquarters in St. Paul, Minnesota, and has an additional office in Beijing, China. Synaptic Medical specializes in cardiac electrophysiology products, including bipolar pacing systems, fixed curve and deflectable diagnostic catheters, pulmonary vein mapping catheters, and ablation technologies. The company's mission is to create innovative, cost-effective, and clinically advanced solutions that enhance treatment options for physicians and their patients.

Hasten is a pharmaceutical manufacturing company that integrates R&D, manufacturing, and commercialization, and covers the entire industry chain. They are dedicated to creating China's innovative medical and health company, and they collaborate with key government agencies, medical and health professionals, and industry partners to provide high-quality solutions, build a health management ecosystem, and benefit more patients.

Leo Summit is positioned as a provider of life science laboratory automation solutions. It provides reliable and flexible solutions for the biomedical industry, driven by the demand for automated intelligent technology in clinical medicine and drug R&D industries, and relies on artificial intelligence and motion control technology. Provide systematic intelligent products and solutions for R&D firms, AI pharmaceuticals, and CRO firms in the fields of new medications, synthetic biology, and single-cell sequencing.

Yaneng Biotechnology specializes in molecular diagnostic technology, focusing on gene diagnostic chip platforms. The company offers a range of services, including cervical cancer screening and hereditary disease diagnostics, which encompass pre-pregnancy and prenatal testing. Additionally, Yaneng Biotechnology provides automatic nucleic acid extraction and conducts research and development services. Their portfolio also includes molecular diagnosis solutions and medical laboratory services aimed at addressing conditions such as cervical cancer and hepatitis.

RVAC Medicines is an mRNA platform company founded in 2021 and based in Singapore. It focuses on developing a diverse pipeline of innovative vaccines and therapeutics to address unmet medical needs, particularly in emerging markets. The company is dedicated to producing cutting-edge mRNA and nucleic acid delivery technologies through its advanced GMP manufacturing facilities. RVAC Medicines offers end-to-end manufacturing capabilities and supports process scale-up and technology transfer, allowing for the development of both single and multi-mRNA/DNA products. This infrastructure aims to empower healthcare professionals in their efforts to combat infectious diseases.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

Adcentrx Therapeutics is a biotechnology company dedicated to advancing the development of protein conjugate therapeutics aimed at treating cancer and other serious diseases. The company focuses on creating targeted therapies that leverage the precise targeting capabilities of biologics combined with the therapeutic effectiveness of small molecule payloads. Through its innovative approach, Adcentrx seeks to enhance patient treatment options, offering next-generation therapies that aim to improve outcomes for individuals facing life-threatening conditions.

AffaMed Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative pharmaceutical products. The company focuses on accelerating the clinical development of new therapies aimed at addressing significant unmet medical needs, particularly in the fields of ophthalmology, neurology, and psychiatry. By targeting these critical areas, AffaMed strives to create impactful solutions that improve the lives of patients globally.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

I-Mab Biopharma (Shanghai) Co., Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, with additional offices in Beijing and Rockville, Maryland. Founded in 2016, the company focuses on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the fields of immuno-oncology and immuno-inflammation. I-Mab's diverse drug pipeline targets various therapeutic areas, including multiple myeloma, autoimmune diseases, pediatric growth hormone deficiency, and several cancer indications such as head and neck cancer. Key candidates in its portfolio include Uliledlimab, an antibody for solid tumors, along with Ragistomig and Givastomig, highlighting the company's commitment to developing transformative therapies for patients.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.

The Chain Medical Labs is a professional independent medical laboratory established from a team of experienced technical and management experts which is one of the Shanghai Chain medical investment management Inc. also alliance with few internationally renowned lab and vendors. The company utilize advanced testing methods, quality management systems, automation technology as Europe, America and Japan for their Clinical Diagnostics. CMLabs features in clinical laboratory services, clinical trial services, research services, and laboratory information system services to support all medical institutions, as well as assist to obtain ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process and external audit services.

CMAB BioPharm is a biopharmaceutical service firm based in Suzhou, China, specializing in process development and manufacturing services for biologic products. Established in 2017, the company offers customized development and manufacturing solutions for antibodies and biologics, catering to both domestic and international clients. CMAB BioPharm's services include process development, GMP manufacturing, and the production of aseptic drug products, adhering to stringent quality standards. The firm supports its customers through all stages of drug development, providing comprehensive solutions for preclinical and clinical phases, from initial DNA sequences to commercial production.

CMAB BioPharm is a biopharmaceutical service firm based in Suzhou, China, specializing in process development and manufacturing services for biologic products. Established in 2017, the company offers customized development and manufacturing solutions for antibodies and biologics, catering to both domestic and international clients. CMAB BioPharm's services include process development, GMP manufacturing, and the production of aseptic drug products, adhering to stringent quality standards. The firm supports its customers through all stages of drug development, providing comprehensive solutions for preclinical and clinical phases, from initial DNA sequences to commercial production.

I-Mab Biopharma (Shanghai) Co., Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, with additional offices in Beijing and Rockville, Maryland. Founded in 2016, the company focuses on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the fields of immuno-oncology and immuno-inflammation. I-Mab's diverse drug pipeline targets various therapeutic areas, including multiple myeloma, autoimmune diseases, pediatric growth hormone deficiency, and several cancer indications such as head and neck cancer. Key candidates in its portfolio include Uliledlimab, an antibody for solid tumors, along with Ragistomig and Givastomig, highlighting the company's commitment to developing transformative therapies for patients.

Anrei Medical, established in 2006 and based in Hangzhou, China, is a wholly owned and FDA registered enterprise specializing in the development and manufacturing of disposable medical devices for minimally invasive procedures. The company focuses on devices used in various digestive surgeries, including gastroscopy and endoscopic retrograde cholangiopancreatography (ERCP). Anrei Medical is vertically integrated, overseeing all aspects of its operations from research and development to distribution and customer service, ensuring a comprehensive approach to meeting the needs of the healthcare market. Its established sales network allows it to effectively reach a wide range of customers, positioning the company as a key player in the medical device industry.

Ascletis Pharma Inc. is a biotechnology company engaged in the research, development, manufacturing, marketing, and sale of pharmaceutical products primarily in Mainland China and internationally. The company specializes in therapies for viral infections and liver diseases, offering products such as Ganovo, a direct-acting antiviral for hepatitis C, and Pegasys, a pegylated interferon for hepatitis B and C. Its product pipeline includes ASC22, a PD-L1 antibody fragment in Phase II trials for chronic hepatitis B, ASC40, a fatty acid synthase inhibitor poised for Phase II trials targeting non-alcoholic steatohepatitis, and ASC41, an oral THR-ß agonist for the same condition. Additionally, Ascletis is advancing therapies for HIV and liver cancer, with several products in clinical and pre-clinical stages. Founded in 2014 and headquartered in Hangzhou, China, Ascletis aims to leverage both international innovation and local market efficiencies to establish a sustainable and profitable business model in the evolving pharmaceutical landscape.

I-Mab Biopharma (Shanghai) Co., Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, with additional offices in Beijing and Rockville, Maryland. Founded in 2016, the company focuses on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the fields of immuno-oncology and immuno-inflammation. I-Mab's diverse drug pipeline targets various therapeutic areas, including multiple myeloma, autoimmune diseases, pediatric growth hormone deficiency, and several cancer indications such as head and neck cancer. Key candidates in its portfolio include Uliledlimab, an antibody for solid tumors, along with Ragistomig and Givastomig, highlighting the company's commitment to developing transformative therapies for patients.

FitSAMO is an orthopaedic surgical equipment supplier.

Ascletis Pharma Inc. is a biotechnology company engaged in the research, development, manufacturing, marketing, and sale of pharmaceutical products primarily in Mainland China and internationally. The company specializes in therapies for viral infections and liver diseases, offering products such as Ganovo, a direct-acting antiviral for hepatitis C, and Pegasys, a pegylated interferon for hepatitis B and C. Its product pipeline includes ASC22, a PD-L1 antibody fragment in Phase II trials for chronic hepatitis B, ASC40, a fatty acid synthase inhibitor poised for Phase II trials targeting non-alcoholic steatohepatitis, and ASC41, an oral THR-ß agonist for the same condition. Additionally, Ascletis is advancing therapies for HIV and liver cancer, with several products in clinical and pre-clinical stages. Founded in 2014 and headquartered in Hangzhou, China, Ascletis aims to leverage both international innovation and local market efficiencies to establish a sustainable and profitable business model in the evolving pharmaceutical landscape.

FitSAMO is an orthopaedic surgical equipment supplier.

Clarus Therapeutics is a men's health specialty pharmaceutical company based in Northbrook, Illinois, founded in 2003. The company specializes in the development and commercialization of oral testosterone replacement therapies in the United States. Its primary product, JATENZO, is a soft gel formulation of testosterone undecanoate, designed to treat men with low testosterone levels, also known as hypogonadism. JATENZO is notable for being the first and only oral testosterone replacement therapy available, serving as the sole source of revenue for Clarus Therapeutics. In addition to JATENZO, the company is also engaged in the development of other androgen-based medications for both men and women.